


PRODUCT INFORMATION



Lasofoxifene (tartrate)

Item No. 17646

CAS Registry No.: 190791-29-8
Formal Name: (5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol, (2S,3S)-2,3-dihydroxybutanedioate
Synonym: CP 336,156
MF: C₂₈H₃₁NO₂ • C₄H₆O₆
FW: 563.6
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lasofoxifene (tartrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the lasofoxifene (tartrate) in the solvent of choice, which should be purged with an inert gas. Lasofoxifene (tartrate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of lasofoxifene (tartrate) in these solvents is approximately 1 mg/ml.

Lasofoxifene (tartrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lasofoxifene (tartrate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Lasofoxifene (tartrate) has a solubility of approximately 0.25 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Lasofoxifene is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). It selectively binds to human ER α with an IC₅₀ value of 1.5 nM and inhibits bone loss in ovariectomized rats.¹ In clinical studies of postmenopausal osteoporosis, 0.5 mg/day lasofoxifene was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.^{2,3} Lasofoxifene has also been shown to act as an inverse agonist at the CB₂ cannabinoid receptor, indicating its potential to be repurposed as a therapeutic for indications wherein CB₂ is a target.⁴

References

1. Ke, H.Z., Paralkar, V.M., Grasser, W.A., et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. *Endocrinology* **139**(4), 2068-2076 (1998).
2. Cummings, S.R., Ensrud, K., Delmas, P.D., et al. Lasofoxifene in postmenopausal women with osteoporosis. *N. Engl. J. Med.* **362**(8), 686-696 (2010).
3. Gennari, L., Merlotti, D., and Nuti, R. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: Focus on lasofoxifene. *Clin. Interv. Aging* **5**, 19-29 (2010).
4. Kumar, P. and Song, Z.-H. CB₂ cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene. *Biochem. Bioph. Res. Co.* **443**, 144-149 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM